International clamour over Germany’s seizure of Indian generics shipment - update
This article was originally published in SRA
Another seizure of an Indian-manufactured generic drug by a customs authority in the European Union has fuelled concern that the EU’s enforcement of intellectual property rights regulations is delaying access to essential medicines in developing countries.
You may also be interested in...
Sponsors of new and existing medicines in New Zealand will have to update their product labels within specified deadlines to include warning statements about certain allergens.
A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.
Companies are being encouraged to become “early adopters” of the EU Clinical Trials Information System when it goes live in December 2021.